ClinicalTrials.Veeva

Menu

Maintaining Cochlear Patency After VIIIth Nerve Surgery

Henry Ford Health logo

Henry Ford Health

Status

Withdrawn

Conditions

Acoustic Neuroma
Labyrinthitis Ossificans
Profound Hearing Impairment

Treatments

Device: MedEl Test Electrode Placer

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03261726
IRB# 1040241

Details and patient eligibility

About

Tumors arising from the VIIIth Nerve (vestibulo-cochlear nerve) typically present with progressive unilateral hearing loss and tinnitus. VIIIth Nerve tumors with documented growth on serial MRI scans typically lead to deafness in the affected ear over time. Radiation (Gamma Knife® or stereotactic radiosurgery) may preserve hearing in ~80% while surgery (middle cranial fossa or retrosigmoid approach) may preserve hearing in 16 - 40% of small tumors, although initial hearing preservation by both modalities may fail over time. Surgical resection via the translabyrinthine approach is the safest way to remove many of these tumors, but involves loss of all hearing. In all treatment modalities, the vascular supply (the labyrinthine artery, a terminal branch of AICA with no collaterals) to the cochlea is at risk. After devascularization, the cochlea frequently fills with fibrous tissue or ossifies (labyrinthitis ossificans), making it impossible to place a cochlear implant should it be required later. The incidence of this is 46% in our patients. This study seeks to determine the feasibility of preserving the cochlear duct with an obdurator so that patients undergoing translabyrinthine removal of VIIIth nerve tumors may retain the option of a cochlear implant at a later time.

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients of all ages with unilateral or bilateral acoustic neuromas who face loss of hearing in 1 ear from surgical removal via a translabyrinthine approach.
  • patients do not meet criteria for conventional cochlear implantation or auditory brainstem implantation.
  • tumor removal must allow preservation of the auditory division of the VIIIth cranial nerve.
  • the patient must be willing to undergo preoperative S pneumococcus immunization protocol recommended by the US CDC immunization recommendations for cochlear implant patients.

Exclusion criteria

  • inability to preserve the auditory division of the VIIIth cranial nerve during tumor removal ossification or fibrosis of the cochlea found on preoperative imaging (CT or MRI) that precludes cochlear implantation.
  • active middle ear disease.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

MedEl Test Electrode Placer
Experimental group
Description:
MedEl Test Electrode Placed at VIIIth nerve tumor resection
Treatment:
Device: MedEl Test Electrode Placer

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems